A Ardern-Jones
Overview
Explore the profile of A Ardern-Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
636
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moynihan C, Bancroft E, Mitra A, Ardern-Jones A, Castro E, Page E, et al.
Psychooncology
. 2017 Aug;
26(11):1987-1993.
PMID: 28812325
Objective: Increased risk of prostate cancer (PCa) is observed in men with BRCA1/BRCA2 mutations. Sex and gender are key determinants of health and disease although unequal care exists between the...
2.
Mitra A, Bancroft E, Barbachano Y, Page E, Foster C, Jameson C, et al.
BJU Int
. 2010 Sep;
107(1):28-39.
PMID: 20840664
Objective: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte...
3.
Bancroft E, Locke I, Ardern-Jones A, DMello L, McReynolds K, Lennard F, et al.
J Med Genet
. 2010 May;
47(7):486-91.
PMID: 20472659
Background: A novel oncogenetic clinic was established in 2002 at the Royal Marsden NHS Foundation Trust offering advice and specialist follow-up for families with a germline mutation in BRCA1 or...
4.
Clyne M, Offman J, Shanley S, Virgo J, Radulovic M, Wang Y, et al.
Br J Cancer
. 2009 Jan;
100(2):376-80.
PMID: 19142183
Germline mutations in the mismatch repair (MMR) genes are associated with Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Here, we characterise a variant of hMLH1 that...
5.
Ormondroyd E, Moynihan C, Ardern-Jones A, Eeles R, Foster C, Davolls S, et al.
Psychooncology
. 2008 Aug;
17(8):804-11.
PMID: 18688787
Objectives: This study explores communication within families of clinically significant genetics research results, after the death of the patient participant. BRCA2 mutations were found in several men after their death...
6.
Shanley S, Myhill K, Doherty R, Ardern-Jones A, Hall S, Vince C, et al.
Fam Cancer
. 2007 May;
6(2):213-9.
PMID: 17508269
We have conducted a telelink telephone-led cancer genetic counselling model at The Royal Marsden NHS Foundation Trust. The study commenced in March 2004 and evaluation of the clinic was conducted...
7.
Ormondroyd E, Moynihan C, Watson M, Foster C, Davolls S, Ardern-Jones A, et al.
J Genet Couns
. 2007 May;
16(4):527-38.
PMID: 17492498
When a gene mutation is identified in a research study following the death of the study participant, it is not clear whether such information should be made available to relatives....
8.
Kote-Jarai Z, Salmon A, Mengitsu T, Copeland M, Ardern-Jones A, Locke I, et al.
Br J Cancer
. 2006 Jan;
94(2):308-10.
PMID: 16404418
Deleterious mutations in the BRCA1 gene predispose women to an increased risk of breast and ovarian cancer. Many functional studies have suggested that BRCA1 has a role in DNA damage...
9.
Hallowell N, Ardern-Jones A, Eeles R, Foster C, Lucassen A, Moynihan C, et al.
J Genet Couns
. 2005 Jun;
14(3):207-17.
PMID: 15959652
Men who have a family history of breast and/or ovarian cancer may be offered a predictive genetic test to determine whether or not they carry the family specific BRCA1/2 mutation....
10.
Ardern-Jones A, Kenen R, Eeles R
Eur J Cancer Care (Engl)
. 2005 Jun;
14(3):272-81.
PMID: 15952973
Recent research suggests that women who develop breast cancer between the ages of 30-34 may have specific tumour characteristics: Those with high grade, oestrogen receptor negative, human epidermal growth factor...